New Statutory Auditor appointed; Executive Director takes on CFO role
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved: (1) M/s. K B Nambiar & Associates as new Statutory Auditors for 5 years (FY26-27 to FY30-31), replacing M/s. Srinaga & Giridharan who completed their 2nd term. (2) Existing Executive Director Mr. Tejagna K. Katpitia additionally designated as CFO and KMP from Sept 3, 2026. (3) Directors Report for FY25-26 approved. (4) 31st AGM on Sept 30, 2026 at 11:30 AM via video conferencing. E-voting Sept 27-29, 2026.
Routine auditor rotation after completing two terms. CFO shift to an internal Executive Director signals leadership continuity. No material impact on shareholders.